12th Annual Next Generation Sequencing & Clinical Diagnostics Congress04 - 06 November 2020, GMT (UTC+0)

An outstanding and comprehensive programme discussing key areas shaping next generation sequencing, drug development and personalised healthcare. Case studies include integration of NGS to clinical development to personalised therapies and innovative treatments.

Last Year's Event Included...

Over 800 attendees representing internationally renowned academic institutions, research institutes and hospitals as well as global pharmaceutical organisations and leading biotech companies.

Over 80 case studies, presentations, panel discussions focused on the key issues in microbiome research, multi omics data integration, delivering genome-based medicine, spatial transcriptomics, single cell analysis emerging trends and single cell analysis in drug research & development.

PLUS interactive opportunities including:

  • Panel Discussions
  • Pre-Event Webinars
  • Pre-Event Speaker Q&As and Spotlights

Agenda at a Glance

Pre-Event Deep Dive Sessions

  • Microbiome Methodologies
  • Single Cell Proteomics
  • Clinical Diagnostics & Precision Medicine Multi-Technology Session

Day One

  • Delivering Genomic-Based Medicine
  • Multi Omics Data Integration & NGS Informatics

Day Two

  • Part 1 – Long & Short Read Sequencing
  • Part 2 – Data Analysis & Management

Live Webinar

Genomic Testing Strategies For Research Through To Clinical Studies: Profiling Of Genomics From NeoGenomics' Perspective

As genomic technologies develop and mature, adoption moves from the research environment into the clinical setting.  Previously, where Sanger and qPCR were the most rational choices to commercialize a diagnostic, NGS has become the biomarker testing methodology of choice.  Additionally, other emerging technologies and platforms like NanoString are finding their way into clinical trials as well as routine diagnostics.  With advances in technology, biomarker testing strategies have also evolved with a trend toward higher order multiplexed technologies as well as cross modality testing from a single sample to understand correlations between DNA, RNA and protein markers.  More data may be over burdensome to analyze, while a focused assay may miss an opportunity for collecting potentially valuable data.  Without a straightforward “rule of thumb” for which genomics technology to use when, thoughtful consultation is required.  This presentation will discuss the various factors and consideration points for choosing a genomic biomarker testing strategy to support biomarker projects.

Presented by James Yen, Senior Scientific Manager, CDx Programs, NeoGenomics

Thursday, 25 June 2020 | 15:30 BST